Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Brain Scans Give Clues to Link Between Alzheimer’s, Down Syndrome, /i> Reveals

It’s long been known that people with Down syndrome are at higher risk for Alzheimer’s disease. Now, research suggests that changes in the brains of people with Down syndrome, as seen on brain scans, might help lead to promising treatments that could delay or prevent Alzheimer’s. “We and other researchers have been interested in detecting […]

Read More »

Merck’s Keytruda shrinks lung cancer tumors, FDA approval sought

Merck & Co Inc’s Keytruda, approved for treating melanoma, was shown in a trial to shrink tumors in nearly half of advanced lung cancer patients with high levels of a protein used by tumors to evade the body’s own disease-fighting cells. The company said it has filed for U.S. Food and Drug Administration approval of […]

Read More »

KEYTRUDA, Merck’s Anti-PD-1 Therapy, Demonstrates Superior Survival, Progression Free Survival and Overall Response Rate Compared to Ipilimumab an Anti-CTLA-4 Therapy…

PHILADELPHIA–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from the randomized, pivotal Phase 3 study, KEYNOTE-006, in the treatment of unresectable advanced melanoma. In the study, KEYTRUDA® (pembrolizumab) was statistically superior to ipilimumab for progression-free survival (PFS), overall survival (OS), and overall response rate (ORR). On March 24, […]

Read More »

Early Findings with KEYTRUDA, Merck’s Anti-PD-1 Therapy, in Patients with Advanced Pleural Mesothelioma Presented at AACR Annual Meeting

PHILADELPHIA–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of data investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in 25 patients with advanced pleural mesothelioma, a difficult-to-treat cancer of the lining of the lungs, abdomen and other organs. The early findings presented showed an […]

Read More »

Peloton Therapeutics Inc. Presents Promising Data on First Inhibitor of HIF-2α for Renal Cell Carcinoma at 2015 AACR Annual Meeting

DALLAS & PHILADELPHIA–(BUSINESS WIRE)–Peloton Therapeutics Inc., a drug discovery and development company focused on advancing first-in-class, small molecule cancer therapies targeting unexploited molecular vulnerabilities, presented preclinical data on its lead investigational candidate, PT2385, at the American Association for Cancer Research Annual Meeting in Philadelphia, PA. PT2385 is the first clinical stage antagonist of hypoxia inducible […]

Read More »

Full Data on Baxter’s Investigational Recombinant Treatment BAX 111 Supports Potential Role to Treat von Willebrand Disease

Baxter International Inc. today presented additional data from the Phase III clinical trial of BAX 111, the first highly-purified recombinant von Willebrand Factor (rVWF) in clinical development as a treatment for patients with von Willebrand disease, the most common type of inherited bleeding disorder.1 The data were presented as an Abstract of Distinction during an […]

Read More »

ReNeuron stem cell therapy shows long-term promise for stroke

A pioneering stem cell treatment for patients disabled by stroke has continued to show long-term promise in a clinical trial, the British biotech company behind the project said on Friday. News that two-year follow-up data from a small Phase I study showed improvements in limb function with no worrying safety issues lifted shares in ReNeuron […]

Read More »

Obesity link to prostate cancer may vary by race

Obesity may be partly responsible for higher rates of prostate cancer observed among African American men, suggests a new U.S. study. The links between obesity and prostate cancer among different races is complex, researchers say, but if emphasis is put on keeping people at a healthy weight, the excess burden of this cancer among African […]

Read More »

Athersys stroke treatment fails study, shares slide

Athersys Inc’s stem-cell therapy, its only product to reach human trials, failed a mid-stage study testing it as a treatment for a type of stroke, wiping off more than 40 percent of the company’s market value. Data showed on Friday that patients given the therapy, MultiStem, did not show a significant difference from those given […]

Read More »

AstraZeneca lung cancer drug delays disease by more than a year

An experimental lung cancer pill from AstraZeneca delays disease progression by more than a year, according to new data presented at a medical meeting on Friday. AZD9291, which the company expects to file for U.S. approval in the second quarter of 2015, is one of a number of cancer medicines AstraZeneca is hoping will rebuild […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!

Subscribe

Ad Right Bottom